Matrix metalloproteinases and clinical and functional status in smokers with persistent asthma

Abstract


AIM. To assess the role of matrix metalloproteinases (MMP) in the clinical and functional status of smoking patients with persistent asthma. MATERIALS AND METHODS. Examinations were made in 16 healthy smokers (a control group), 22 healthy nonsmoking volunteers (a volunteer group), and 16 patients with endogenous (n=6) and mixed (n=10) persistent asthma (a study group) with varying disease control. The investigators used the following techniques: spirometry; determination of airway resistance and FeCO in the expired air; 30-minute percutaneous monitoring of blood oxygenation and 6-minute walk test; enzyme immunoassay for matrix metalloproteinase levels. RESULTS. The longer duration and higher intensity of smoking increase airway inflammation in the asthmatic patients and the length of blood oxygenation within the very low range. The combined negative influence of tobacco smoking and the underlying disease leads to a clinically significant decrease in pulmonary ventilation ability and basic levels of blood oxygenation, the occurring asthma control reduction being correlating with the longer duration of treatment. The investigators revealed the predictors of lowering the mean level of blood oxygenation (MMP-9, FeCO, and airway resistance), as well as the factors that negatively influence the level of dyspnea and fatigue in asthmatic smokers. CONCLUSION. The serum levels of FeCO and MMP-9 may serve as markers reflecting the intensity of airway inflammation in smokers with persistent asthma.

Full Text

Restricted Access

About the authors

V V Gnoevykh

Email: valvik@inbox.ru

T P Gening

Iu A Portnova

T V Abakumova

A Iu Smirnova

D R Dolgova

References

  1. Букреева Е.Б., Богушевич С.А., Дементьев Е.А. Экзогенные и эндогенные факторы формирования хронической обструктивной болезни легких. Бюл Сиб мед 2003; 1: 75-78.
  2. Гамбарян М.Г. Факторы риска обструктивной болезни легких, их взаимосвязь и прогностическая значимость. Пульмонология 2006; 3: 2-76.
  3. Глобальная стратегия лечения и профилактики бронхиальной астмы. (Global Initiative for Asthma, GINA), 2009 г. (http://www.ginasthma.org.).
  4. Чучалин А.Г. Сахарова Г.М., Новиков К.Ю. Практическое руководство по лечению табачной зависимости. Рус мед журн 2001; 9: 904-911.
  5. Гноевых В.В. Математическое моделирование ранних никотинассоциированных дисфункций пульмо-кардиальной системы на начальных этапах развития ХОБЛ. Пульмонология 2007; 2: 63-67.
  6. Гноевых В.В., Смирнова А.Ю., Портнова Ю.А. и др. Клиническое значение повышенной чувствительности дыхательной системы к табачному дыму у больных персистирующей бронхиальной астмой. Рос мед журн 2012; 4: 13-16.
  7. Смирнова А.Ю., Гноевых В.В., Шалашова Е.А. и др. Клиническое значение дисфункций пульмокардиальной системы у курильщиков с персистирующей бронхиальной астмой. Рос мед журн 2011; 4: 9-13.
  8. Невзорова В.А., Тилик Т.В., Гилифанов Е.А. и др. Роль матриксных металлопротеиназ в формировании морфофункционального дисбаланса воздухоносных путей при хронической обструктивной болезни легких. Тихоокеанс мед журн 2011; 2: 9-13.
  9. Фомина В.В. Роль системы матриксных металлопротеиназ в патогенезе профессиональных заболеваний органов дыхания: Автореф. дис. ... канд. мед. наук. М 2010; 24.
  10. Dalal S., Imai K., Mercer B. et al. A role for collagenase (matrix mettaloproteinase-1) in pulmonary emphysema. Chest 2000; 117: 227S-228S.
  11. Minematsu N., Nakamura H., Taneto H. et al. Genetic polymorphim in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 2001; 289 (1): 116-119.
  12. Russell R.E., Culpitt S.V., DeMatos C. et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002; 26: 602-609.
  13. Ганусевич И.И. Роль матриксных металлопротеиназ (ММП) при злокачественных новообразованиях. Характеристика ММП, регуляция их активности, прогностическое значение. Онкология 2010; 1: 10-16.
  14. Vignola A.M., Riccobono L., Mirabella A. et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158: 1945-1950.
  15. Candelario-Jalil E., Yang Y., Rosenberg G.A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009; 158 (3): 983-984.
  16. Miyazaki Y., Hara A., Kato K. The effect of hypoxic microenvironment on matrix metalloproteinase expression in xenografts of human oral squamous cell carcinoma. Int J Oncol 2008; 32 (1): 145-151.
  17. Osinsky S., Ganusevich I., Bubnovskaya L. Hypoxia level and matrix metalloproteinases-2 and -9 activity in Lewis lung carcinoma: correlation with metastasis. Exp Oncol 2005; 27: 202-205.
  18. Shapiro S.D., Ingenito E.P. The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. Am J Respir Cell Mol Biol 2005; 32: 367-372.
  19. Beeh K.M., Beier J., Kornmann O., Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor o metalloprotmease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003; 97: 634-639.
  20. Finlay G.A., Russell K.J., McMahon K.J. et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997; 52: 502-506.
  21. Imai K., Dalai S.S., Chen E.S. et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med 2001; 163: 786-791.
  22. Russell R.E., Thorley A., Culpitt S.V. el al. Alveolar macrophage-mediated elastolysis: roles ofmatrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 2002; 283: L867-873.

Statistics

Views

Abstract - 37

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies